Dabigatran for stroke prevention in nonvalvular atrial fibrillation: Focus in the geriatric population

Consultant Pharmacist

Volumn 29, Issue 3, 2014, Pages 169-178

  Brunetti, Luigi ^a   Chen, Clement ^b   Jentora, J ^c  

^a RUTGERS UNIVERSITY   (United States)

^b Veterans Affairs Hudson Valley Healthcare System   (United States)

^c Phoenix Marketing Solutions   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Bleeding; Dabigatran; Nonvalvular atrial fibrillation; Stroke

Indexed keywords

AMIODARONE; CLARITHROMYCIN; DABIGATRAN; DABIGATRAN ETEXILATE; DRONEDARONE; KETOCONAZOLE; QUINIDINE; VERAPAMIL;

AGING; ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; BLEEDING; CASE REPORT; CEREBROVASCULAR ACCIDENT; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY DISEASE; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; OBSERVATIONAL STUDY; POPULATION RESEARCH; POST HOC ANALYSIS; POSTMARKETING SURVEILLANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW;

ABNORMAL RENAL/LIVER FUNCTION, STROKE, BLEEDING, LABILE INR, ELDERLY AND CONCOMITANT DRUG/ALCOHOL USE; ACCF = AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION; ACCP = AMERICAN COLLEGE OF CHEST PHYSICIANS; AF = ATRIAL FIBRILLATION; AHA = AMERICAN HEART ASSOCIATION; ANTICOAGULATION; APT = ACTIVATED PARTIAL THROMBOPLASTIN TIME; ATRIA = ANTICOAGULATION AND RISK FACTORS IN ATRIAL FIBRILLATION; ATRIAL FIBRILLATION; BLEEDING; CHADS2 = CONGESTIVE HEART FAILURE, HYPERTENSION, AGE ≯ 75 YEARS, DIABETES MELLITUS, STROKE; CI = CONFIDENCE INTERVAL; CLCR = CREATININE CLEARANCE; DABIGATRAN; ECT = ECARIN CLOTTING TIME; FDA = FOOD AND DRUG ADMINISTRATION; FEIBA = FACTOR EIGHT INHIBITOR BYPASS ACTIVITY; FFP = FRESH FROZEN PLASMA; GI = GASTROINTESTINAL; HAS-BLED = HYPERTENSION; HEMORR2HAGES = HEPATIC OR RENAL DISEASE, ETHANOL ABUSE, MALIGNANCY, OLDER AGE, REDUCED PLATELET COUNT OR FUNCTION, REBLEEDING, HYPERTENSION, ANEMIA, GENETIC FACTORS, EXCESSIVE FALL RISK AND STROKE; HR = HAZARD RATIO; INR = INTERNATIONAL NORMALIZED RATIO; ISMP = INSTITUTE FOR SAFE MEDICATION PRACTICES; NONVALVULAR ATRIAL FIBRILLATION; NVAF = NONVALVULAR ATRIAL FIBRILLATION; OBRI = OUTPATIENT BLEEDING RISK INDEX; P-GP = P-GLYCOPROTEIN; PCC = PROTHROMBIN COMPLEX CONCENTRATE; RE-LY = RANDOMIZED EVALUATION OF LONG TERM ANTICOAGULANT THERAPY; RVIIA = RECOMBINANT FACTOR VIIA; SCR = SERUM CREATININE; STROKE; TT = THROMBIN TIME;

AGED; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; DRUG INTERACTIONS; HEMORRHAGE; HUMANS; RISK FACTORS; STROKE;

EID: 84895739662     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2014.169     Document Type: Review

References (69)

1. Wann LS, Curtis AB, Ellenbogen KA et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm 2011;8:e1-8.
2. Sellers MB, Newby LK. Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. Am Heart J 2011;161:241-6.
3. Pugh D, Pugh J, Mead GE. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing 2011;40:675-83.
4. Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded. Arch Intern Med 2003;163:1580-6. (Pubitemid 36835103)
5. van Walraven C, Hart RG, Connolly S et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 2009;40:1410-6.
6. Robert-Ebadi H, Le Gal G, Righini M. Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging 2009;4:165-77.
7. Riva N, Smith DE, Lip GY et al. Advancing age and bleeding risk are the strongest barriers to anticoagulant prescription in atrial fibrillation. Age Ageing 2011;40:653-5.
8. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013;368:1272-4.
9. Larsen TB, Rasmussen LH, Skjoth F et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013;61:2264-73.
10. Berger R, Salhanick SD, Chase M et al. Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin. Ann Emerg Med 2013;61:475-9.
11. Sorensen R, Gislason G, Torp-Pedersen C et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open 2013;3.
12. Pradaxa® [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; March 2011.
13. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011;123:1436-50.
14. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009;15 Suppl 1:9S-16S.
15. Steffel J, Braunwald E. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. Eur Heart J 2011;32:1968-76, 76a.
16. Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelgatran. Handb Exp Pharmacol 2010;196:407-18.
17. Brunetti L, Bandali F. Dabigatran: is there a role for coagulation assays in guiding therapy? Ann Pharmacother 2013;47:828-40.
18. Schulman S, Majeed A. The oral thrombin inhibitor dabigatran: strengths and weaknesses. Semin Thromb Hemost 2012;38:7-15.
19. Wann LS, Curtis AB, Ellenbogen KA et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2011;57:1330-7.
20. Guyatt GH, Akl EA, Crowther M et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:7S-47S.
21. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
22. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Dabigatran etexilate. Advisory committee briefing document, August 27, 2010. http://www.Fda.Gov/downloads/ advisorycommittees/ committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ ucm226009.pdf. Accessed November 1, 2012.
23. Gage BF, Yan Y, Milligan PE et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151:713-9. (Pubitemid 43290267)
24. You JJ, Singer DE, Howard PA et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e531S-75S.
25. Mason PK, Lake DE, DiMarco J et al. Impact of CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. Am J Med 2012;125:603.e1-603.e6.
26. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105:91-9. (Pubitemid 28405230)
27. Pisters R, Lane DA, Nieuwlaat R et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-100.
28. Fang MC, Go AS, Chang Y et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J Am Coll Cardiol 2011;58:395-401.
29. Roldan V, Marin F, Fernandez H et al. Predictive value of the HASBLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. Chest 2013;143:179-84.
30. Apostolakis S, Lane DA, Guo Y et al. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 2012;60:861-7.
31. Dager WE, Kiser TH. Systemic anticoagulation considerations in chronic kidney disease. Adv Chronic Kidney Dis 2010;17:420-7.
32. Pradaxa® European Medicines Agency. Accessed at http://www. ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000829/ WC500041059.pdf.
33. Pradaxa® Canadian prescribing information. Accessed at http://www. boehringer-ingelheim.ca/en/Home/Human-Health/Our-Products/ Product-Monographs/ Pradax-pm.pdf.
34. ISMP Medication Safety Alert. 2012;17.
35. Radecki RP. Dabigatran: uncharted waters and potential harms. Ann Intern Med 2012;157:66-8.
36. Legrand M, Mateo J, Aribaud A et al. The use of dabigatran in elderly patients. Arch Intern Med 2011;171:1285-6.
37. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012;366:864-6.
38. Dowling TC, Wang ES, Ferrucci L et al. Glomerular filtration rate equations overestimate creatinine clearance in older individuals enrolled in the Baltimore Longitudinal Study on Aging: Impact on Renal Drug Dosing. Pharmacotherapy 2013;33:912-21.
39. Hariharan S, Madabushi R. Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmacol 2012;52:119S-25S.
40. Lehr T, Haertter S, Liesenfeld KH et al. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol 2012;52:1373-8.
41. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004;57:6-14. (Pubitemid 38067945)
42. Stangier J, Stahle H, Rathgen K et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008;47:47-59. (Pubitemid 350260888)
43. Eikelboom JW, Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123:2363-72.
44. Beasley BN, Unger EF, Temple R. Anticoagulant options - why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med 2011;364:1788-90.
45. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003;139:893-900.
46. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011;31:326-43.
47. Hartter S, Sennewald R, Nehmiz G et al. Oral bioavailability of dabigatran etexilate (Pradaxa®) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol 2013;75:1053-62.
48. Chin P, Vella-Brincat J, Walker S et al. Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital. Intern Med J 2013;43:778-83.
49. Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother 2012;46:e10.
50. Barton CA, McMillian WD, Sadi Raza S et al. Hemopericardium in a patient treated with dabigatran etexilate. Pharmacotherapy 2012;32:e103-7.
51. Bene J, Said W, Rannou M et al. Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients. Ann Pharmacother 2012;46:e14.
52. Chen BC, Sheth NR, Dadzie KA et al. Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose. Am J Kidney Dis 2013;62:591-4.
53. Harinstein LM, Morgan JW, Russo N. Treatment of dabigatranassociated bleeding: case report and review of the literature. J Pharm Pract 2013;26:264-9.
54. Lillo-Le Louet A, Wolf M, Soufir L et al. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation. Thromb Haemost 2012;108:583-5.
55. Bleeding with dabigatran (Pradaxa). Med Lett Drugs Ther 2011;53:98.
56. Dumkow LE, Voss JR, Peters M et al. Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma. Am J Health Syst Pharm 2012;69:1646-50.
57. Hartnell NR, Wilson JP. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 2004;24:743-9. (Pubitemid 38747859)
58. Siegal DM, Crowther MA. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J 2013;34:489-98b.
59. Schiele F, van Ryn J, Canada K et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013;121:3554-62.
60. Heidbuchel H, Verhamme P, Alings M et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-51.
61. Weitz JI, Quinlan DJ, Eikelboom JW. Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation 2012;126:2428-32.
62. Pengo V, Crippa L, Falanga A et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011;106:868-76.
63. van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27.
64. Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis 2013;61:487-9.
65. Morgenstern LB, Hemphill JC 3rd, Anderson C et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke 2010;41:2108-29.
66. Dager WE, Gosselin RC, Roberts AJ. Reversing dabigatran in lifethreatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med 2013;41:e42-6.
67. Cano EL, Miyares MA. Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother 2012;10:160-3.
68. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation - developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-413.
69. Mack DR, Kim JJ. Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation. Ann Pharmacother 2012;46:1105-10.